{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-12596"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-12596","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"IFNγ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy","abstract":"CAR-T therapy has improved overall and complete response rates, andprolonged progression free survival of patients with relapsed/refractory hematological malignancies. The short-term and long-term impacts of anti-CD19 CAR-T products on the immune landscape of B cell malignancies has garnered considerable attention in recent years. Most notably, a subset of patients experience high-grade cytokine toxicities, including cytokine release syndrome and immune cell-associated hematologic toxicity that manifest as prolonged cytopenia. Whereas etiology of CRS is more well established, the mechanisms leading to CAR-T associated cytopenia remains elusive. Rejeski et. al. showed that severe cytopenia in patients post CAR-T treatment led to frequent infections and increased hospitalizations. Onset of cytopenia was associated with worse survival owing to non-relapse mortality in patients post CAR-T treatment, thereby emphasizing the need to address these hematological toxicities. An observation drawn from two independent clinical trials was the co-occurrence of cytopenia with CRS. Among the cytopenias neutropenia was most predominant, where the decline in neutrophils intensified with the grade of CRS. We utilized an IL-2Rα knockout mouse model to recapitulate cytokine toxicities with elevated levels of IL6, IFNγ, and TNFα and increased M1-like-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to a disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils, and adecrease in proliferative and mature neutrophils. Both non-tumor-bearing and Eμ- ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNγ-blockade alleviated both CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive cooccurrence of CRS and neutropenia in an IFNγ-dependent manner, leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNγ-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNγ-blockade to reduce CRS and neutropenia.","abstract_html":"CAR-T therapy has improved overall and complete response rates, andprolonged progression free survival of patients with relapsed/refractory hematological malignancies. The short-term and long-term impacts of anti-CD19 CAR-T products on the immune landscape of B cell malignancies has garnered considerable attention in recent years. Most notably, a subset of patients experience high-grade cytokine toxicities, including cytokine release syndrome and immune cell-associated hematologic toxicity that manifest as prolonged cytopenia. Whereas etiology of CRS is more well established, the mechanisms leading to CAR-T associated cytopenia remains elusive. Rejeski et. al. showed that severe cytopenia in patients post CAR-T treatment led to frequent infections and increased hospitalizations. Onset of cytopenia was associated with worse survival owing to non-relapse mortality in patients post CAR-T treatment, thereby emphasizing the need to address these hematological toxicities. An observation drawn from two independent clinical trials was the co-occurrence of cytopenia with CRS. Among the cytopenias neutropenia was most predominant, where the decline in neutrophils intensified with the grade of CRS. We utilized an IL-2Rα knockout mouse model to recapitulate cytokine toxicities with elevated levels of IL6, IFNγ, and TNFα and increased M1-like-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to a disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils, and adecrease in proliferative and mature neutrophils. Both non-tumor-bearing and Eμ- ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNγ-blockade alleviated both CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive cooccurrence of CRS and neutropenia in an IFNγ-dependent manner, leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNγ-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNγ-blockade to reduce CRS and neutropenia.","abstract_has_math":false,"creators":["Goala, Payal"],"institution":"University of South Florida","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Biology (Cell Biology, Microbiology, Molecular Biology)","degree_department":null,"school":null,"contributors":["Marco L. Davila,MD, Ph.D.","Michael D. Jain,MD, Ph.D.","Paulo Rodriguez, Ph.D.","Jose Alejandro Guevara,MD, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-12-10T08:00:00Z","date_published":"2025-12-10T08:00:00Z","updated_at":"2026-11-19T08:51:54Z","subjects":["Anti-CD19","CAR-T Therapy","B Cell Acute lymphoblastic Leukemia","Cytokine Release Syndrome","Neutropenia","IFNγ-blockade","IL-2Rα","Regulatory T cells","Immunology and Infectious Disease","Oncology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/11293","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/11293","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-12596","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Marco L. Davila,MD, Ph.D.","Michael D. Jain,MD, Ph.D.","Paulo Rodriguez, Ph.D.","Jose Alejandro Guevara,MD, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Goala, Payal"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-12-10T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biology (Cell Biology, Microbiology, Molecular Biology)"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Anti-CD19","CAR-T Therapy","B Cell Acute lymphoblastic Leukemia","Cytokine Release Syndrome","Neutropenia","IFNγ-blockade","IL-2Rα","Regulatory T cells","Immunology and Infectious Disease","Oncology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/11293"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["CAR-T therapy has improved overall and complete response rates, andprolonged progression free survival of patients with relapsed/refractory hematological malignancies. The short-term and long-term impacts of anti-CD19 CAR-T products on the immune landscape of B cell malignancies has garnered considerable attention in recent years. Most notably, a subset of patients experience high-grade cytokine toxicities, including cytokine release syndrome and immune cell-associated hematologic toxicity that manifest as prolonged cytopenia. Whereas etiology of CRS is more well established, the mechanisms leading to CAR-T associated cytopenia remains elusive. Rejeski et. al. showed that severe cytopenia in patients post CAR-T treatment led to frequent infections and increased hospitalizations. Onset of cytopenia was associated with worse survival owing to non-relapse mortality in patients post CAR-T treatment, thereby emphasizing the need to address these hematological toxicities. An observation drawn from two independent clinical trials was the co-occurrence of cytopenia with CRS. Among the cytopenias neutropenia was most predominant, where the decline in neutrophils intensified with the grade of CRS. We utilized an IL-2Rα knockout mouse model to recapitulate cytokine toxicities with elevated levels of IL6, IFNγ, and TNFα and increased M1-like-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to a disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils, and adecrease in proliferative and mature neutrophils. Both non-tumor-bearing and Eμ- ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNγ-blockade alleviated both CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive cooccurrence of CRS and neutropenia in an IFNγ-dependent manner, leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNγ-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNγ-blockade to reduce CRS and neutropenia."]},{"key":"dc:title","label":"Title","values":["IFNγ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy"]}]}],"canonical_facts":{"dc:contributor":["Marco L. Davila,MD, Ph.D.","Michael D. Jain,MD, Ph.D.","Paulo Rodriguez, Ph.D.","Jose Alejandro Guevara,MD, Ph.D."],"dc:creator":["Goala, Payal"],"dc:date":["2025-12-10T08:00:00Z"],"dc:description":["CAR-T therapy has improved overall and complete response rates, andprolonged progression free survival of patients with relapsed/refractory hematological malignancies. The short-term and long-term impacts of anti-CD19 CAR-T products on the immune landscape of B cell malignancies has garnered considerable attention in recent years. Most notably, a subset of patients experience high-grade cytokine toxicities, including cytokine release syndrome and immune cell-associated hematologic toxicity that manifest as prolonged cytopenia. Whereas etiology of CRS is more well established, the mechanisms leading to CAR-T associated cytopenia remains elusive. Rejeski et. al. showed that severe cytopenia in patients post CAR-T treatment led to frequent infections and increased hospitalizations. Onset of cytopenia was associated with worse survival owing to non-relapse mortality in patients post CAR-T treatment, thereby emphasizing the need to address these hematological toxicities. An observation drawn from two independent clinical trials was the co-occurrence of cytopenia with CRS. Among the cytopenias neutropenia was most predominant, where the decline in neutrophils intensified with the grade of CRS. We utilized an IL-2Rα knockout mouse model to recapitulate cytokine toxicities with elevated levels of IL6, IFNγ, and TNFα and increased M1-like-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to a disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils, and adecrease in proliferative and mature neutrophils. Both non-tumor-bearing and Eμ- ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNγ-blockade alleviated both CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive cooccurrence of CRS and neutropenia in an IFNγ-dependent manner, leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNγ-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNγ-blockade to reduce CRS and neutropenia."],"dc:identifier":["https://digitalcommons.usf.edu/etd/11293"],"dc:subject":["Anti-CD19","CAR-T Therapy","B Cell Acute lymphoblastic Leukemia","Cytokine Release Syndrome","Neutropenia","IFNγ-blockade","IL-2Rα","Regulatory T cells","Immunology and Infectious Disease","Oncology"],"dc:title":["IFNγ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy"],"thesis:degree_discipline":["Biology (Cell Biology, Microbiology, Molecular Biology)"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:51:54Z"}